Publications

February 2023

A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA

February 2023

Phase I results of a phase I/II study of Pembrolizumab and AR Signaling Inhibitor (ARSI) +/- Ac-J591 for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

April 2022

Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody Ac-J591 and beta-radiolabeled ligand Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)

February 2022

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC)

June 2021

Phase 1 study of Ac-J591 for men with metastatic castration-resistant prostate cancer

May 2020

Dose-escalation results of a phase I trial of Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC)